{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"submitter":["Montoya M"],"funding":["NINDS NIH HHS","NCI NIH HHS","NIGMS NIH HHS"],"pubmed_abstract":["<h4>Background</h4>Glioblastoma (GBM) has a highly immunosuppressive tumor immune microenvironment (TIME), largely mediated by myeloid-derived suppressor cells (MDSCs). Here, we utilized a retroviral replicating vector (RRV) to deliver Interferon Regulatory Factor 8 (IRF8), a master regulator of type 1 conventional dendritic cell (cDC1) development, in a syngeneic murine GBM model. We hypothesized that RRV-mediated delivery of IRF8 could \"reprogram\" intratumoral MDSCs into antigen-presenting cells (APCs) and thereby restore T-cell responses.<h4>Methods</h4>Effects of RRV-IRF8 on survival and tumor growth kinetics were examined in the SB28 murine GBM model. Immunophenotype was analyzed by flow cytometry and gene expression assays. We assayed functional immunosuppression and antigen presenta"],"journal":["bioRxiv : the preprint server for biology"],"pagination":["2024.04.02.587608"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11014587"],"repository":["biostudies-literature"],"pubmed_title":["IRF8-driven reprogramming of the immune microenvironment enhances anti-tumor adaptive immunity and reduces immunosuppression in murine glioblastoma."],"pmcid":["PMC11014587"],"funding_grant_id":["R35 NS105068","T32 CA151022","R25 GM056847"],"pubmed_authors":["Montoya M","Okada H","Kasahara N","Chuntova P","Collins SA","Patel TS","Nejo T","Yamamichi A"],"additional_accession":[]},"is_claimable":false,"name":"IRF8-driven reprogramming of the immune microenvironment enhances anti-tumor adaptive immunity and reduces immunosuppression in murine glioblastoma.","description":"<h4>Background</h4>Glioblastoma (GBM) has a highly immunosuppressive tumor immune microenvironment (TIME), largely mediated by myeloid-derived suppressor cells (MDSCs). Here, we utilized a retroviral replicating vector (RRV) to deliver Interferon Regulatory Factor 8 (IRF8), a master regulator of type 1 conventional dendritic cell (cDC1) development, in a syngeneic murine GBM model. We hypothesized that RRV-mediated delivery of IRF8 could \"reprogram\" intratumoral MDSCs into antigen-presenting cells (APCs) and thereby restore T-cell responses.<h4>Methods</h4>Effects of RRV-IRF8 on survival and tumor growth kinetics were examined in the SB28 murine GBM model. Immunophenotype was analyzed by flow cytometry and gene expression assays. We assayed functional immunosuppression and antigen presenta","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Apr","modification":"2026-05-26T14:04:08.871Z","creation":"2026-05-25T03:07:02.606Z"},"accession":"S-EPMC11014587","cross_references":{"pubmed":["38617245"],"doi":["10.1101/2024.04.02.587608"]}}